EGFR and cancer: This suggests that Cys307 plays a crucial role in EGFR activation and dimerization through redox regulation, and its disruption in the EGFRvIII mutant may contribute to oncogenic signalling, highlighting its potential as a therapeutic target in redox-driven EGFR activation and cancer progression.